REG - Arecor Therapeutics - Arecor and Sequel Med Tech to host fireside panel

Arecor TherapeuticsAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251209:nRSI7151Ka&default-theme=true

RNS Number : 7151K  Arecor Therapeutics PLC  09 December 2025

Arecor Therapeutics plc

("Arecor" or the "Company")

 

Arecor and Sequel Med Tech to host virtual fireside panel discussion

 

·    Key Opinion Leader commentary on the treatment journey for people
with diabetes and factors driving future innovation

·    Discussion around Arecor and Sequel's next generation insulin-AID
system co-development deal; what's next for the future of the insulin/pump
market

 

Cambridge, UK, 9 December 2025: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company focused on drug development and delivery in diabetes
and other cardiometabolic diseases, and Sequel Med Tech LLC ("Sequel"), a
company developing state-of-the-art insulin delivery technologies, will be
hosting a virtual fireside panel discussion on Wednesday 7 January at 16:00
GMT / 11:00 ET / 08:00 PT.

Speakers will include Dr Sarah Howell, CEO of Arecor, Dr Alan Lotvin, MD, CEO
and Co-Founder of Sequel, and Thomas Blevins MD, FACE, FNLA, Endocrinologist
and Key Opinion Leader on the Diabetes sector. The session will be chaired by
Melanie Senior, Healthcare Writer and Analyst.

Topics to be discussed include the treatment journey for people with diabetes
and the healthcare professional's experience; the current diabetes AID system
market and the factors driving innovation; Arecor's AT278 ultra-concentrated,
ultra-rapid insulin in development; Sequel's twiist device and its launch in
the US; the next steps for both companies as they co-develop AT278 and the
twiist device. Finally, a discussion about what's next for the diabetes /
insulin pump sector; what are people with diabetes on intensive insulin
therapy looking for in order to lower the daily management burden and improve
outcomes. The session will conclude with a Q&A session.

To register for the event, please email arecor@vigoconsulting.com or
Investors@SequelMedTech.com.

-ENDS-

For more information, please contact:

 

 Arecor Therapeutics plc                                 +44 (0) 1223 426060

Dr Sarah Howell, Chief Executive Officer

David Ellam, Chief Financial Officer                   info@arecor.com

 Singer Capital Markets Advisory LLP                     +44 (0) 20 7496 3000

(NOMAD and Broker to Arecor Therapeutics)
 Phil Davies, Andrew Johnson, James Todd

 Vigo Consulting (IR and PR for Arecor)                  +44 (0) 20 7390 0230
 Melanie Toyne-Sewell, Rozi Morris

                                                         arecor@vigoconsulting.com

 Sequel Med Tech LLC                                     Investors@SequelMedTech.com

 Gabby Fernandes, VP, Finance & Investor Relations

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a clinical stage biopharmaceutical company focused
on drug development and delivery in diabetes and other cardiometabolic
diseases. The Company is applying its proprietary technology platform,
Arestat®, to develop a portfolio of proprietary products, as well as working
with leading pharmaceutical and biotechnology companies to deliver therapeutic
products. Its lead product is AT278, the only ultra-concentrated (500U/mL)
ultra-rapid acting insulin. Arecor is also developing a novel oral delivery
platform for peptides (e.g. GLP-1 receptor agonists) targeting the obesity and
diabetes markets. The Company is listed on AIM (AIM: AREC) and is based in
Cambridge, UK.  For further details please see www.arecor.com
(http://www.arecor.com) .

Arecor® and Arestat® are registered trademarks of Arecor Limited.

About AT278

AT278 is a novel proprietary formulation of an existing insulin, designed to
accelerate the absorption of insulin post injection even at very high
concentrations (500U/mL). With its best-in-class profile, it has the potential
to disrupt the market for insulin treatment as the first concentrated, yet
very rapid acting insulin for the growing population of people with diabetes
with high daily insulin needs as well as to act as a critical enabler in the
development of next-generation, miniaturised longer wear automated insulin
delivery (AID) systems.

About Sequel Med Tech

Headquartered in Manchester, New Hampshire, US, Sequel is developing the next
generation of transformative drug-delivery advancements. Sequel's approach is
to look at diabetes management holistically to advance systems that make
living with diabetes simpler and easier for all. Sequel was co-founded by
visionary Dean Kamen, serial entrepreneur Pablo Legorreta, seasoned medical
device executive Bill Doyle and healthcare leader Alan Lotvin, MD. Sequel's
focus is to bring the latest developments in science and technology to the
marketplace, helping drive more accessible drug delivery. For more
information, please visit www.sequelmedtech.com
(https://www.sequelmedtech.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAXAPEELSFFA



            Copyright 2019 Regulatory News Service, all rights reserved